A Novel Therapy for Urinary Tract Infections UTIs are the most common bacterial infections affecting 400 million people per year worldwide, with a treatment market is estimated at $9.89 billion. Up to 80% of UTIs are caused by uropathogenic E. coli that regularly form...
Advanced Antimicrobial Surface Testing Wirral SME, SafeClimb designs, manufactures and maintains height safety equipment, including safety ropes and harnesses, for industrial and leisure markets worldwide. Due to enhanced cleaning regimens adopted during the COVID-19...
Revolutionising Healthcare Cystic fibrosis (CF) is a genetic disease that affects around 11,000 people in the UK, and over 160,000 globally. One of the most important bugs that causes this is Pseudomonas aeruginosa – a bacterium that is present everywhere but rarely...
COST Action Biofilm RegulatoryToolBox NBIC are pleased to be co-leading the EU COST Action CA23152: RegulatoryToolBox ‘Building Consensus on Biofilm Regulatory Decision Making’, which officially launched on 26 October 2024 with a meeting in Brussels, attended by...
National Biofilms Innovation Centre Annual Report 2024 The National Biofilms Innovation Centre (NBIC) Annual Report 2024 is now available to download. This report covers our key achievements to date and our future plans. Download Annual Report 2024 Foreword – A...
